{"id":"cozaar-plus-pro-tab","safety":{"commonSideEffects":[{"rate":"10","effect":"Dizziness"},{"rate":"3","effect":"Fatigue"},{"rate":"2-3","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"1-2","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL216386","moleculeType":"Protein","molecularWeight":"1119.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to vasodilation, reduced peripheral resistance, and decreased blood pressure. The 'pro tab' formulation likely refers to a combination or enhanced delivery form marketed by Hanmi Pharmaceutical.","oneSentence":"Cozaar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:19.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Diabetic nephropathy in patients with type 2 diabetes"},{"name":"Reduction of cardiovascular risk in hypertensive patients"}]},"trialDetails":[{"nctId":"NCT00496834","phase":"PHASE4","title":"LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02-01","conditions":"Hypertension","enrollment":201},{"nctId":"NCT01828359","phase":"PHASE4","title":"The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-08","conditions":"Hypertension","enrollment":199}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Losartan 100mg/ HCTZ 12.5mg"],"phase":"marketed","status":"active","brandName":"Cozaar® plus pro tab","genericName":"Cozaar® plus pro tab","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cozaar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Reduction of cardiovascular risk in hypertensive patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}